Biohaven Pharmaceutical Holding Company Ltd. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Biohaven Pharmaceutical Holding Company Ltd. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $42.82 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-10.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2020-11-09
- Biohaven Pharmaceutical Holding Company Ltd. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2020-06-30 was $0.00.
- Biohaven Pharmaceutical Holding Company Ltd. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2020-03-31 was $42.82M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month |
|---|---|---|
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $42.82M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $42.82M 10-Q · filed 2020-11-09 |